P/B
11,1
Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
$9.4B
Market Cap • 10/30/2026
2006
(20 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
33,2
P/EBITDA
156,5
P/OCF
71,4
P/FCF
71,8
P/E
140,6
BVPS
13
EPS
1,2
Market Cap
Market Cap
9,4B
EV
8,6B
EV/Revenue
30,5
EV/EBITDA
143,6
EV/EBIT
147,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,4%
Total Yield
-0,4%
Payout
0%
Retained Earnings
-304M
Profitability
Gross Margin
100%
EBITDA Margin
21,2%
EBIT Margin
20,7%
Net Margin
29,4%
D&A/EBITDA
0%
R&D/Revenue
62,1%
Capex/Revenue
0,2%
Capex/D&A
39,9%
Capex/OCF
0,5%
SBC/OCF
38%
% PPE
1,2%
% Goodwill
0%
ROE
11%
ROIC
55,5%
Growth
CAGR Revenue 5Y
59,6%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
21,7
Quick Ratio
21,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!